Ross Golen

Director of Business Development - Direct to Pharma at Circuit Clinical

Ross Golen has held various roles in the business development and sales/marketing fields. From 2022 to present, they have been the Director of Business Development - Direct to Pharma at Circuit Clinical. From 2019 to 2022, they were a Business Development Executive - Clinical Trials at Vitalograph, where they were responsible for driving new business, developing and executing area business plans, and building close relationships with prospective customers. From 2017 to 2019, they were the Associate Director of Site Strategy at ClinEdge. From 2015 to 2017, they were the Associate Director of Business Development at BTC Network LLC (formerly BlueTheory Clinical Trials), where their responsibilities included managing day to day business development with a stable of medical research sites and pharmaceutical companies, advocating the BTC site network, and connecting pharmaceutical companies with research sites for clinical trials. From 2006 to 2015, they were the Channels Team Lead at Granite Telecommunications, where they served as a single point of contact for 25+ outside sales agencies, managing accounts totaling $9,000,000 in annual billing. In 2005, they were an International Sales/Marketing Intern at Volkswagen AG in Wolfsburg, Germany.

Ross Golen's education history includes graduating from Dartmouth High School, followed by a Communications Major and German Minor from the University of Massachusetts Amherst in 2006. While at UMass Amherst, they also obtained an ISU Summer Certificate from The Philipp University of Marburg in 2003, as well as a Practicum from Ostfalia - University of Applied Sciences in 2005. In 2020, they completed the Accelerated Management Program - Executive Education at Yale School of Management. Additionally, they obtained a certification in Communicating with Diplomacy and Tact from LinkedIn in December 2022.

Links

Previous companies

Granite logo

Peers

View in org chart

Timeline

  • Director of Business Development - Direct to Pharma

    June, 2022 - present